These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7878933)

  • 41. Mycophenolate mofetil in renal graft recipients with increased immune risk of graft loss.
    Boratyńska M; Magott M; Klinger M; Smolska D; Rychlewska B; Myszka K; Szepietowski T; Szyber P; Patrzalek D
    Transplant Proc; 2002 Mar; 34(2):553-5. PubMed ID: 12009621
    [No Abstract]   [Full Text] [Related]  

  • 42. Protocol core biopsy (CADI): a surrogate marker for chronic rejection. Mycophenolate Mofetil ICM 1866 and IICR 023 Study Groups.
    Yilmaz S; Taskinen E; Paavonen T; Häyry P
    Transplant Proc; 2000 Feb; 32(1A Suppl):12S. PubMed ID: 10686312
    [No Abstract]   [Full Text] [Related]  

  • 43. Treatment of calcineurin inhibitor toxicity by dose reduction plus introduction of mycophenolate mofetil.
    McKane W; Kanganas C; Preston R; Cairns T; Hakim N; Palmer A; Taube D
    Transplant Proc; 2001; 33(1-2):1224-5. PubMed ID: 11267268
    [No Abstract]   [Full Text] [Related]  

  • 44. Use of mycophenolate mofetil in kidney transplant recipients with viral hepatitis infection: is it justified?
    Sumethkul V; Ingsathit A; Leelasa-Nguan P; Jirasiritham S
    Transplant Proc; 2002 Dec; 34(8):3217-9. PubMed ID: 12493425
    [No Abstract]   [Full Text] [Related]  

  • 45. The evolving role of mycophenolate mofetil in renal transplantation.
    Warrens AN
    QJM; 2000 Jan; 93(1):15-20. PubMed ID: 10623777
    [No Abstract]   [Full Text] [Related]  

  • 46. Mycophenolate Mofetil Study.
    Baltzan M; Shoker A; Baltzan R
    Transplantation; 1997 Jan; 63(1):173-4. PubMed ID: 9000687
    [No Abstract]   [Full Text] [Related]  

  • 47. Mycophenolate mofetil-associated enterocolitis.
    Liu TC; Amorosino MS; Cerda S; Farraye FA
    Gastrointest Endosc; 2006 Apr; 63(4):707-8, discussion 708. PubMed ID: 16564882
    [No Abstract]   [Full Text] [Related]  

  • 48. Antilymphocyte antibodies, renal transplantation, and meta-analysis.
    Levey AS; Schmid CH; Lau J
    Ann Intern Med; 1998 May; 128(10):863-5. PubMed ID: 9599200
    [No Abstract]   [Full Text] [Related]  

  • 49. Mycophenolate mofetil to rescue children with acute renal transplant rejection.
    Birkeland SA
    Lancet; 1996 Jun; 347(9016):1699-700. PubMed ID: 8642993
    [No Abstract]   [Full Text] [Related]  

  • 50. Prolongation of dog renal allograft survival by RS-61443, a new, potent immunosuppressive agent.
    Platz KP; Eckhoff DE; Hullett DA; Sollinger HW
    Transplant Proc; 1991 Feb; 23(1 Pt 1):497-8. PubMed ID: 1990598
    [No Abstract]   [Full Text] [Related]  

  • 51. Mycophenolate mofetil for transplantation: new drug, old problems?
    Gray DW
    Lancet; 1995 Aug; 346(8972):390. PubMed ID: 7623565
    [No Abstract]   [Full Text] [Related]  

  • 52. Immunosuppression with mycophenolic acid: one size does not fit all.
    Bennett WM
    J Am Soc Nephrol; 2003 Sep; 14(9):2414-6. PubMed ID: 12937322
    [No Abstract]   [Full Text] [Related]  

  • 53. Immunosuppressant substitutes in liver transplantation.
    Ascher NL
    Lancet; 2001 Feb; 357(9256):571-2. PubMed ID: 11558477
    [No Abstract]   [Full Text] [Related]  

  • 54. Questionable long-term benefit of mycophenolate.
    Steiner RW
    Transplantation; 2000 Jul; 70(2):401. PubMed ID: 10933174
    [No Abstract]   [Full Text] [Related]  

  • 55. Diarrhea in a post-renal transplant child: questions.
    Wiley JR; Shivaram P; Resnick JM; Fish DL; Park RW; Haws RM
    Pediatr Nephrol; 2015 Apr; 30(4):589-90, 591-3. PubMed ID: 24165966
    [No Abstract]   [Full Text] [Related]  

  • 56. Mycophenolate-update after it has come of age.
    Grinyó JM
    Nephrol Dial Transplant; 1999 Jan; 14(1):31-4. PubMed ID: 10052471
    [No Abstract]   [Full Text] [Related]  

  • 57. The cost effectiveness of mycophenolate mofetil in the first year after living related renal transplantation.
    Süleymanlar G; Tuncer M; Sarikaya M; Ersoy F; Aktan S; Yakupoğlu G; Karpuzoğlu T
    Transplant Proc; 2001 Aug; 33(5):2780-1. PubMed ID: 11498158
    [No Abstract]   [Full Text] [Related]  

  • 58. Use of non-absorbable polypropylene mesh for the treatment of spontaneous renal graft rupture.
    Vales-Albertos LJ; Cueto-Manzano AM; Valdespino C; Gómez B
    Rev Invest Clin; 2006; 58(1):78-9. PubMed ID: 16789602
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adverse events in renal transplantation under tacrolimus/mycophnolate mofetil immunosuppression: a single-center experience.
    Omoto K; Tanabe K; Tokumoto T; Ishida H; Shimmura H; Makiyama K; Toma H
    Transplant Proc; 2002 Aug; 34(5):1821-2. PubMed ID: 12176591
    [No Abstract]   [Full Text] [Related]  

  • 60. In vivo pharmacodynamics of Atgam induction immunosuppression in renal transplantation.
    Henell KR; Norman DJ
    Transplant Proc; 1995 Feb; 27(1):1052-3. PubMed ID: 7878800
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.